Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
Sun Yat-sen University
Sun Yat-sen University
University of Alabama at Birmingham
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
University of Pisa
Montefiore Medical Center
Georgetown University
King Faisal Specialist Hospital & Research Center
Alliance for Clinical Trials in Oncology
University of Southern California
University of California, Irvine
NYU Langone Health
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Mayo Clinic
University Health Network, Toronto
University of Pittsburgh
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
University of Southern California
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
University Hospital, Rouen